Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

131.36USD
16 Aug 2019
Change (% chg)

$0.82 (+0.63%)
Prev Close
$130.54
Open
$131.61
Day's High
$131.65
Day's Low
$130.61
Volume
1,792,996
Avg. Vol
2,050,461
52-wk High
$148.97
52-wk Low
$122.00

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson Reports Q2 Adjusted EPS Of $2.58
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Johnson & Johnson ::REPORTS 2019 SECOND-QUARTER RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $2.58.Q2 EARNINGS PER SHARE $2.08.Q2 EARNINGS PER SHARE ESTIMATE $2.46 -- REFINITIV IBES DATA.Q2 REVENUE $20.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $20.29 BILLION.OPERATIONAL SALES GUIDANCE INCREASED DUE TO STRENGTH OF BUSINESS; EPS GUIDANCE RANGE MAINTAINED.QTRLY OPERATIONAL GROWTH OF 1.6% AND ADJUSTED OPERATIONAL GROWTH OF 3.7%."PIPELINES CONTINUE TO PROGRESS WITH LAUNCH OF NEW PRODUCTS AND SEVERAL REGULATORY SUBMISSIONS AND APPROVALS".QTRLY PHARMACEUTICAL WORLDWIDE OPERATIONAL SALES, EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES GREW 4.4%.QTRLY GAAP NET LITIGATION EXPENSE $409 MILLION VERSUS $703 MILLION.SEES FY 2019 ADJUSTED OPERATIONAL SALES CHANGE VERSUS. PRIOR YEAR 3.2% - 3.7%.SEES FY ADJUSTED EPS $8.53 TO $8.63.QTRLY WORLDWIDE REMICADE SALES $1,107 MILLION VERSUS $1,320 MILLION.SEES FY 2019 OPERATIONAL SALES $82.4 BILLION TO $83.2 BILLION.QTRLY WORLDWIDE IMBRUVICA SALES $831 MILLION VERSUS $620 MILLION.SEES FY 2019 ESTIMATED REPORTED SALES $80.8 BILLION TO $81.6 BILLION.FY2019 EARNINGS PER SHARE VIEW $8.60, REVENUE VIEW $81.22 BILLION -- REFINITIV IBES DATA.QTRLY WORLDWIDE ZYTIGA SALES $698 MILLION VERSUS $909 MILLION.QTRLY WORLDWIDE STELARA SALES $1,558 MILLION VERSUS $1,341 MILLION.  Full Article

Johnson & Johnson Sets Quarterly Cash Dividend Of $0.95 Per Share
Monday, 15 Jul 2019 

July 15 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR THIRD QUARTER 2019.SETS QUARTERLY CASH DIVIDEND OF $0.95PER SHARE.  Full Article

J&J Poised To Test Experimental HIV Vaccine In U.S. And Europe, Starting Later This Year - Bloomberg
Friday, 12 Jul 2019 

July 12 (Reuters) - :JOHNSON & JOHNSON IS POISED TO TEST AN EXPERIMENTAL HIV VACCINE IN THE U.S. AND EUROPE, STARTING LATER THIS YEAR - BLOOMBERG.  Full Article

Tracon Pharmaceuticals Provides Update On Phase 1/2 Trial Of Trc253
Tuesday, 2 Jul 2019 

July 2 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1/2 TRIAL OF TRC253 IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER.TRACON PHARMACEUTICALS INC - PHASE 1 DATA PUBLISHED IN ASCO PROCEEDINGS DETERMINED RECOMMENDED PHASE 2 DOSE.TRACON PHARMACEUTICALS INC - ADDITIONAL COHORT OF PATIENTS WITH A SPECIFIC ANDROGEN RECEPTOR POINT MUTATION ADDED TO ONGOING PHASE 2 STUDY.TRACON PHARMACEUTICALS INC - PHASE 2 DATA EXPECTED IN 2(ND) HALF 2020; POTENTIAL FOR $45 MILLION OPT-IN PAYMENT FROM JANSSEN.TRACON PHARMACEUTICALS INC - TRC253 WAS WELL-TOLERATED AND NO DRUG-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED.  Full Article

Janssen Receives Positive CHMP Opinion Recommending Expanded Use Of Imbruvica
Friday, 28 Jun 2019 

June 28 (Reuters) - JANSSEN::JANSSEN RECEIVES POSITIVE CHMP OPINION RECOMMENDING EXPANDED USE OF IMBRUVICA®▼(IBRUTINIB) IN TWO INDICATIONS IN EUROPE.JANSSEN - ONE RECOMMENDATION IS FOR USE OF IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB IN ADULT PATIENTS WITH PREVIOUSLY UNTREATED CLL.JANSSEN - SECOND RECOMMENDATION IS FOR USE OF IBRUTINIB PLUS RITUXIMAB FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA.  Full Article

Genmab Announces U.S. FDA Approval Of Darzalex In Combination With Lenalidomide And Dexamethasone
Thursday, 27 Jun 2019 

June 27 (Reuters) - Genmab A/S ::GENMAB ANNOUNCES U.S. FDA APPROVAL OF DARZALEX® (DARATUMUMAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN FRONTLINE MULTIPLE MYELOMA.GENMAB - APPROVAL OF DARZALEX (DARATUMUMAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE BASED ON PHASE III MAIA STUDY.  Full Article

Janssen Pharma Says Erleada Met Main Goal In Phase 3 Titan Study
Friday, 31 May 2019 

May 31 (Reuters) - Johnson & Johnson ::ERLEADA® (APALUTAMIDE) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL (OS) AND RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (RPFS) IN PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC).JANSSEN PHARMA - ERLEADA SIGNIFICANTLY IMPROVED OS AND RPFS IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER PATIENTS.JANSSEN PHARMA - PHASE 3 TITAN STUDY MET SECONDARY ENDPOINT OF PROLONGED TIME TO CYTOTOXIC CHEMOTHERAPY IN PATIENTS TREATED WITH ERLEADA PLUS ADT.JANSSEN PHARMA - PHASE 3 TITAN STUDY ALSO MET PRIMARY DUAL ENDPOINTS OF OS AND RPFS.JANSSEN PHARMA - TREATMENT DISCONTINUATION DUE TO AES WAS 8 PERCENT IN ERLEADA ARM COMPARED TO 5 PERCENT IN PLACEBO ARM IN TITAN 3 STUDY.  Full Article

J&J Confirms $300 Mln Punitive Award In Olson Talc Trial
Friday, 31 May 2019 

May 31 (Reuters) - Johnson & Johnson ::J&J CONFIRMS $300 MILLION PUNITIVE AWARD IN OLSON TALC TRIAL, WHICH IS ON TOP OF $25 MILLION COMPENSATORY DAMAGES AWARDED LAST WEEK - SPOKESWOMAN.TRIAL HAD "SIGNIFICANT LEGAL AND EVIDENTIARY ERRORS" WHICH CO BELIEVES WILL WARRANT REVERSAL ON APPEAL - SPOKESWOMAN.  Full Article

Janssen Pharmaceutical - U.S. FDA Grants Priority Review Of Invokana (Canagliflozin) SNDA For The Treatment Of Chronic Kidney Disease In Patients With Type 2 Diabetes
Wednesday, 22 May 2019 

May 22 (Reuters) - Johnson & Johnson ::U.S. FDA GRANTS PRIORITY REVIEW OF INVOKANA® (CANAGLIFLOZIN) SNDA FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES.JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON - U.S. FDA HAS GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL NEW DRUG APPLICATION FOR INVOKANA.  Full Article

Johnson & Johnson Says New York Jury Awarded $25 Million In Compensatory Damages In Lawsuit Alleging Talc Caused Cancer
Tuesday, 21 May 2019 

Johnson & Johnson ::SAYS NEW YORK JURY AWARDED $25 MILLION IN COMPENSATORY DAMAGES IN LAWSUIT ALLEGING TALC CAUSED CANCER.  Full Article

UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.